Interview: New EFPIA President On The Future Of Innovation
Jean-Christophe Tellier, the new president of EFPIA, tells the Pink Sheet why "connected health care" is the key to the future of innovation, how stakeholders should work collaboratively to address the affordability of new therapies, and why Brexit must not lead to fragmentation of the health care network in Europe.
You may also be interested in...
The provision of “express” freight capacity for medicines that need to be delivered urgently is among the latest proposals from the UK government to help cope with supply disruptions in the event of a no-deal Brexit. But the biopharmaceutical industry says some of the proposals are too short notice and will place additional burdens on companies.
Projects on T cells and advanced therapy medicinal products for rare diseases, patient reported outcomes in cancer clinical trials, and improvements to patient drug information are among the latest topics to be offered funding under Europe’s Innovative Medicines Initiative.
Cross-country collaboration on pricing and reimbursement will only work if they are based on certain overarching principles, says the European Federation of Pharmaceutical Industries and Associations.